You are here:

adalimumab (Humira)

Advice

in the absence of a submission from the holder of the marketing authorisation

adalimumab (Humira®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: adalimumab (Humira)
SMC Drug ID: 1305/18
Manufacturer: AbbVie Ltd
Indication: Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 15 January 2018

Back